Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMNM
STRONG SELLImmunome, Inc. · Healthcare · United States · $2.5B · Avg Vol: $36M/d
COMPANY DESCRIPTION
Immunome, Inc. is a biotechnology company dedicated to developing first-in-class targeted oncology therapies, including antibody-drug conjugates (ADCs) and radiopharmaceuticals. The company's competitive moat is driven by its proprietary discovery engine, which identifies novel antibody-target pairs directly from patients who have successfully fought off disease. It operates as an innovative platform-based biotech with strategic collaborations in the high-growth oncology sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 14.0M | 9.0M | 6.9M | -29.6% | 4.0M | 2.7M | 64.6M | 205.1% |
| EPS | -0.33 | -2.05 | -5.00 | -2.43 | — | -2.38 | -2.12 | -2.12 | — |
| Shares | 113.3M | 113.3M | 64.5M | 113.1M | -0.1% | 113.3M | — | — | — |
| Debt | 0.3M | 1.6M | 4.8M | 3.9M | 136.6% | 3.7M | — | — | — |
| Equity | 16.7M | 119.9M | 181.2M | 634.3M | 236.5% | — | — | — | — |
| Op CF | -28.7M | -7.6M | -110.8M | -190.9M | — | -196.5M | — | — | — |
| Inv CF | -0.2M | -30.5M | -85.1M | 60.8M | — | — | — | — | — |
| Fin CF | 32.0K | 116.4M | 240.5M | 640.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMNM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMNM | Immunome, Inc.(you) | $2.5B | 17 | STRONG SELL |
| BEAM | Beam Therapeutics Inc. | $2.6B | 17 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 16 | STRONG SELL |
| NKTR | Nektar Therapeutics | $2.4B | 22 | SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| BHVN | Biohaven Ltd. | $2.2B | 20 | STRONG SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 18 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 16 | STRONG SELL |
| IRON | Disc Medicine, Inc. | $2.8B | 23 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%